Affordable Access

Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta.

Authors
Type
Published Article
Journal
Journal of pediatric endocrinology & metabolism : JPEM
Publication Date
Volume
15
Issue
2
Pages
217–218
Identifiers
PMID: 11874188
Source
Medline

Abstract

We describe a patient with osteogenesis imperfecta type 1A who was treated with growth hormone for 9 years. The treatment resulted in a marked improvement in growth velocity, but four fractures occurred during the pubertal period.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments